Overview
Healthcare technology startups continue to face funding challenges with a tighter funding cycle and smaller deal sizes. Once the darling of the sector, investments in digital health startups began to taper off in 2022 after hitting record highs in 2021. According to data from Galen Growth, global venture capital funding deployed for Q3 in 2023 for digital health declined to the lowest level since 2019. For biotech and medtech startups, the situation is exacerbated by the pandemic affecting their ability to run clinical studies, changes in EU MDR regulation and VC pullback. Despite the challenges, there has been a silver lining for Southeast Asia’s healthcare startups, with region-focused VCs and corporate ventures closing deals in the past 2 years. Join us in a panel discussion with leading VCs and startup founders that have successfully raised funding recently as they provide insights on what it will take for healthcare startups to navigate financing through challenging times.
Come hear from the panel on:
How can healthcare startups stay afloat amidst the global VC downturn
Access to capital at various stages
Real healthcare needs exist regardless of boom or bust cycle
Strategic partnerships with corporate ventures
Startups Pitching:
Revivobio
Digital Life Line
Onward Health Research
Gaitmetrics
Albatroz
Austrianova
Schedule
Date: 11 Apr 2024, Thursday
Time: 2:00 PM - 5:00 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: 32 Carpenter Street, 059911
Speakers
Moderator's Profile:
Mayank Gurnani, Deputy Director , A*STAR
Venture Creation & Growth, Innovation & Enterprise
Speaker's Profile:
Dr Yong Chern Chet, Head of Asia Ecosystem, 22Health Ventures
Chet oversees the development of 22Health Ventures’ Singapore-APAC ecosystem. Prior to joining 22Health, Chet served as the ASEAN Healthcare Industry Lead for Amazon Web Services (AWS) where he was responsible for healthcare go-to-market strategy. He was also the founding Chief Operating Officer for Good Doctor Technology, a startup joint venture between Ping An and Grab where he led cross-geography medical teams and business operations across Southeast Asia. Chet’s career spans over 20 years in a variety of regional healthcare and business transformation/innovation leadership roles; from a medical doctor trained in surgery (orthopaedics) to management at Raffles Medical Group and as Healthcare and Life Sciences Industry Leader for Deloitte Southeast Asia. Other leadership/C-Suite appointments for Chet were with iHH Healthcare Berhad as Parkway Pantai VP/CEO of Parkway Laboratories and Ananda Development PCL as Chief Innovation Officer.
Speaker's Profile:
Alex Tan , CEO, ZICO Capital
Alex Tan is the CEO of ZICO Capital Pte. Ltd. He has closed to 30 years of experience in corporate finance and capital markets, and has overseen the listing of more than 60 companies on the SGX-ST. He was previously the CEO of Canaccord Genuity Singapore, Collins Stewart Singapore, and held leading roles in Philip Securities, Hong Leong Finance and UOB Bank. Alex holds a Bachelor of Science (Physics) (Honours) from the National University of Singapore, and MBA from Nanyang Technological University.
Speaker's Profile:
Rosalind Tan Yan Ching, Partner, Adaptive Capital Partners
Rosalind is a seasoned professional with a decade-long experience in venture capital, having made investments across various technology verticals in Southeast Asia, Asia Pacific, and the US. In her current role at Adaptive Capital Partners, she focuses on early-stage startup investments, with a distinct emphasis on healthtech, medtech, and SEA B2B tech-enabled companies. Over the last two years, Adaptive Capital Partners has navigated and executed five impactful healthtech investments, embodying its commitment to innovation amidst the evolving landscape of healthcare technology. Rosalind holds a PhD in Biophysical Chemistry from the University of Glasgow, an MBA, and has passed all three levels of the CFA (June 2021).
Speaker's Profile:
Dr Andrew Wu, Co-Founder & CEO , Mesh Bio
Dr Andrew Wu is a health technology innovator and start up leader with more than 20 years experience in commercialising biomedical technologies. He is the Co-Founder and CEO of Mesh Bio, a Southeast Asia’s leading deep healthtech startup focused on providing predictive analytics solutions based on foundational digital twin models, for chronic disease diagnosis and management. Andrew was previously COO of Clearbridge Biomedics (now known as Biolidics) developing innovative liquid biopsy cancer diagnostics. He was also Chief Product Officer of Clearbridge Health. Prior to Clearbridge, Andrew was technical director for stem cell banking laboratories across Southeast Asia. He started his career as a bioprocess engineer in the recombinant protein CDMO industry. Andrew holds a Bachelors and PhD in Biochemical Engineering from University College London.
